Related Experiment Video
Updated: Sep 11, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Inflammatory bowel disease does not confer higher disease activity or greater radiographic progression in axial
Patricia Remalante-Rayco1,2, Yassir Daghistani3, Tina Chim1
1Schroeder Arthritis Institute, Toronto Western Hospital, Spondylitis Program, University Health Network, Toronto, ON, Canada.
Objectives:
To examine whether inflammatory bowel disease (IBD) influences disease activity and radiographic progression in patients with axial spondyloarthritis (axSpA).
Methods:
This was a longitudinal cohort study of axSpA patients from a tertiary referral centre. Active axSpA was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI ≥4) in a dataset of 1268 patients. Radiographic progression, defined as a ≥ 2-unit increase in the modified Stoke Ankylosing Spondylitis Score (mSASSS) over 2 years, was evaluated in a subset of 471 patients with available longitudinal radiographic data. Generalized estimating equation models were used to assess associations between IBD and each outcome, adjusting for key confounders.
Results:
Among 1451 axSpA patients, 184 (13%) had IBD. Compared with axSpA-only patients, those with IBD had lower HLA-B27 positivity and higher rates of uveitis, peripheral arthritis and elevated C-reactive protein. However, IBD was not associated with an increased risk of active axSpA (OR 0.98, 95% CI 0.75-1.28) or radiographic progression (OR 1.45, 95% CI 0.78-2.73). Sensitivity analyses accounting for time-varying IBD status confirmed these findings.
Conclusion:
AxSpA-IBD patients exhibited distinct clinical features but did not have worse disease activity or greater radiographic progression than those with axSpA alone. These findings suggest that while IBD and axSpA share overlapping immunopathogenic mechanisms, IBD does not exacerbate axSpA severity. Further research is needed to explore the effects of IBD severity and duration on long-term axSpA outcomes to delineate the interaction between these two diseases.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Drugs for Treatment of Ulcerative Colitis in IBD